Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The Penicillin Allergy Verification and Evaluation Act (PAVE Act) requires Medicare to cover penicillin allergy testing and evaluation as part of seniors' routine preventive health visits, starting January 1, 2027. The bill is based on research showing that over 90 percent of Medicare patients with a penicillin allergy label in their medical records can actually safely take penicillin, and that false allergy labels lead to worse health outcomes, longer hospital stays, and more dangerous infections. The legislation directs doctors to identify seniors with reported penicillin allergies, assess whether their symptoms indicate a true allergy, provide information about the risks of maintaining an incorrect allergy label, and refer patients to allergy specialists when appropriate. Medicare can bill separately for more detailed allergy validation services performed on the same day as a wellness visit. The bill aims to improve antibiotic prescribing practices and patient safety while potentially reducing healthcare costs through a simple screening process incorporated into annual preventive care that seniors already receive.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.